Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

903.45INR
5:53am EDT
Change (% chg)

Rs-46.95 (-4.94%)
Prev Close
Rs950.40
Open
Rs955.00
Day's High
Rs956.00
Day's Low
Rs879.55
Volume
998,265
Avg. Vol
600,349
52-wk High
Rs1,074.90
52-wk Low
Rs671.10

GLEN.NS

Chart for GLEN.NS

About

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and... (more)

Overall

Beta: 0.07
Market Cap(Mil.): Rs268,172.59
Shares Outstanding(Mil.): 282.17
Dividend: 2.00
Yield (%): 0.21

Financials

  GLEN.NS Industry Sector
P/E (TTM): 36.61 36.52 36.51
EPS (TTM): 25.96 -- --
ROI: -- 14.40 13.85
ROE: -- 15.20 14.77

Fitch Assigns Glenmark's USD Notes Final 'BB' Rating

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, August 01 (Fitch) Fitch Ratings has assigned India-based Glenmark Pharmaceuticals Ltd's (Glenmark, BB/Positive) USD200m 4.50% senior unsecured notes due in 2021 a final rating of 'BB'. The final rating is in line with the expected rating assigned on 18 July 2016, and follows the receipt of final documents conforming to information already received. Glenmark will use the proceeds to repay debt at its wholly owned ov

Aug 01 2016

Fitch Assigns First-Time 'BB' Rating to Glenmark Pharmaceuticals

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, July 18 (Fitch) Fitch Ratings has assigned India-based Glenmark Pharmaceuticals Ltd (Glenmark) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BB'. The Outlook is Positive. Fitch has also assigned Glenmark's proposed Reg S notes an expected rating of 'BB(EXP)'. Glenmark's rating incorporates its geographically diversified profile, a demonstrated track record in regulatory compliance and its healthy pr

Jul 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.